Khoo Shih named CEO of Singapore’s ClavystBio
Plus: New CEOs named at Vivoryon and Kytopen, and updates from Avalyn, Ankyra, Indaptus and more
Khoo Shih has become CEO of ClavystBio, an affiliate of Singaporean investment company Temasek. A member of ClavystBio’s founding team in her capacity as managing director of life sciences at Temasek, she had been serving as a senior investment adviser.
ClavystBio’s mandate is to “nurture and build” globally competitive companies in Singapore, Khoo Shih told BioCentury in April, and aims to “make Singapore one of the global life sciences translational hubs.” The new role puts her in a position to “directly shape the company’s vision and strategy,” ClavystBio said...